Luspatercept for anemia

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 3 registered trials.

Why this status

  1. 22 Jan 2021: Trial registered, NCT04717414
  2. 25 Feb 2021: Trial started, NCT04717414
  3. 18 Jul 2023: Trial registered, NCT05949684
  4. 24 Oct 2023: Trial started, NCT05949684

The trials

NCT04717414: An Efficacy and Safety Study of Luspatercept (ACE-536) Versus Placebo in Subjects With Myeloproliferative Neoplasm-Associated Myelofibrosis on Concomitant JAK2 Inhibitor Therapy and Who Require Red Blood Cell Transfusions

State
Under way
Phase
Phase 3
People
313 taking part
Started
25 Feb 2021
Primary completion
26 May 2025
Arms
Experimental Arm: Luspatercept (ACE-536)
Results
Posted on the registry
  1. 22 Jan 2021: Trial registered
  2. 25 Feb 2021: Trial started
  3. 16 Jul 2026: Trial results posted

NCT05949684: ELEMENT-MDS: A Study to Compare the Efficacy and Safety of Luspatercept in Participants With Myelodysplastic Syndrome (MDS) and Anemia Not Receiving Blood Transfusions

State
Under way
Phase
Phase 3
People
402 taking part
Started
24 Oct 2023
Primary completion
24 Mar 2028
Arms
Luspatercept
Results
None posted
  1. 18 Jul 2023: Trial registered
  2. 24 Oct 2023: Trial started

NCT07663864: Luspatercept for CIA in AML

State
Under way
Phase
Phase 1 and Phase 2
People
40 planned
Started
1 Jun 2026
Primary completion
31 Dec 2026
Arms
Rotesip treatment group
Results
None posted
  1. 23 Jun 2026: Trial registered

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.